This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Part IV

BERNARD SCHWARTZ, M.D., Ph.D.

AMA Arch Ophthalmol. 1960;63(4):643-659.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

In the previous papers the design and performance of a perfusion system and the synthetic medium to be used in such a system have been presented.* This paper will describe initial experiments on the use of the system for the culture of the rabbit lens. Eight perfusion experiments were done, each one lasting from two to three days. The first three experiments were designed to establish an optimum flow rate and reduced glutathione (GSH) concentration which were then used for the last five perfusion experiments.

Materials and Methods

Male rabbits weighing 4.5 to 5.5 lb. of the New Zealand white albino strain were used. The animals were killed by air embolism and the eyes enucleated immediately. The method of removing the lens under sterile conditions has been described previously.

Stainless steel surgical loops were used to remove the lens from the anterior face of the vitreous with a minimum . . . [Full Text PDF of this Article]

Author Affiliations
Iowa City

From the Departments of Physiology and Ophthalmology, College of Medicine, State University of Iowa.

Footnotes
Submitted for publication Nov. 23, 1959.

Present address of author: Division of Ophthalmology, Department of Surgery, State University of New York, Downstate Medical Center, Brooklyn 3, N.Y.

Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, in the Department of Physiology in the Graduate College of the State University of Iowa.

This study was supported in part by Grant B-1522 and B-1820 from the National Institute of Neurological Diseases and Blindness and was carried out during a tenure of a Special Clinical Traineeship (BT-322) National Institute of Neurological Diseases and Blindness, United States Public Health Service.